Interferon Induced Focal Segmental Glomerulosclerosis

Kayar, Yusuf; Kayar, Nuket Bayram; Alpay, Nadir; Hamdard, Jamshid; Ekinci, İskender; Emegil, Sebnem; Soydas, Rabia Bag; Baysal, Birol

doi:10.1155/2016/6967378

Cited by 8 publications

(12 citation statements)

References 14 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 As seen in Table 1, IFN-a is complicated by kidney injury. [14][15][16][17][18][19][20] Minimal change disease (MCD) and FSGS are manifestations of podocyte injury, [15][16][17][18] whereas thrombotic microangiopathy (TMA) reflects vascular endothelial damage. 14,19,20 FSGS and MCD present with AKI and high-grade proteinuria after 3 months to 6 years of therapy.…”

Section: Ifn-a Therapymentioning

confidence: 99%

“…14,19,20 FSGS and MCD present with AKI and high-grade proteinuria after 3 months to 6 years of therapy. [15][16][17][18] FSGS generally responds poorly to drug cessation and corticosteroids, whereas MCD is more responsive. TMA occurs after approximately 35 months of IFN-a therapy and is associated with severe AKI and significant mortality.…”

Section: Ifn-a Therapymentioning

confidence: 99%

See 1 more Smart Citation

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

Perazella

Shirali

2018

JASN

131

108

View full text Add to dashboard Cite

Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical practice, such that the subfield of "onco-nephrology" has emerged. Conventional chemotherapeutic drugs and novel agents targeting specific genes/proteins are effective cancer therapies but suffer from a number of adverse kidney effects. An effective avenue of cancer treatment is immunotherapy, which uses drugs that augment immune system-mediated recognition and targeting of tumor cells. As such, leveraging the immune system to target malignant cells represents an important modality in eradicating cancer. IFN and high-dose IL-2 are older immunotherapies used in clinical practice to treat various malignancies, whereas new cancer immunotherapies have emerged over the past decade that offer even more effective treatment options. The immune checkpoint inhibitors are an exciting addition to the cancer immunotherapy armamentarium. Chimeric antigen receptor T cells are also a new immunotherapy used to treat various hematologic malignancies. However, as with the conventional and targeted cancer agents, the immunotherapies are also associated with immune-related adverse effects, which includes nephrotoxicity.

show abstract

Section: Ifn-a Therapymentioning

confidence: 99%

Section: Ifn-a Therapymentioning

confidence: 99%

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

Perazella

Shirali

2018

JASN

131

108

View full text Add to dashboard Cite

show abstract

“…Interferon (11) and bisphosphonates (12,13) have been shown to induce severe forms of FSGS, which may sometimes respond to drug cessation and glucocorticoids. Cases of FSGS associated with severe tubulointerstitial lesions were also reported in patients taking cocaine, heroin, calcineurin inhibitors, or lithium (14)(15)(16).…”

Section: Maladaptive Genetic Infectious and Toxic Risk Factorsmentioning

confidence: 99%

Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association

Podestà

Ponticelli²

2020

Front. Med.

View full text Add to dashboard Cite

Focal segmental glomerulosclerosis (FSGS) is a histological term that describes a pathologic renal entity affecting both adults and children, with a wide array of possible underlying etiologies. Podocyte damage with scarring, the hallmark of this condition, leads to altered permeability of the glomerular barrier, which may result in massive proteinuria and relentless renal function deterioration. A definite cause of focal segmental glomerulosclerosis can be confirmed in a minority of cases, while most forms have been traditionally labeled as primary or idiopathic. Despite this definition, increasing evidence indicates that primary forms are a heterogenous group rather than a single disease entity: several circulating factors that may affect glomerular permeability have been proposed as potential culprits, and both humoral and cellular immunity have been implicated in the pathogenesis of the disease. Consistently, immunosuppressive drugs are considered as the cornerstone of treatment for primary focal segmental glomerulosclerosis, but response to these agents and long-term outcomes are highly variable. In this review we provide a summary of historical and recent advances on the pathogenesis of primary focal segmental glomerulosclerosis, focusing on implications for its differential diagnosis and treatment.

show abstract

“…Podocyte injury, characterized by MCD and FSGS, and vascular endothelial damage manifested as TMA are the major sites of nephrotoxicity. 65,[68][69][70][71][72][73]…”

Section: Ifn Therapy and Nephrotoxicitymentioning

confidence: 99%

The adverse kidney effects of cancer immunotherapies

Saly

Perazella

2018

Journal of Onco-Nephrology

View full text Add to dashboard Cite

Cancer therapies are a common cause of acute and chronic kidney disease, which are increasingly being seen by nephrologists in clinical practice. Conventional chemotherapeutic drugs and novel targeted agents are effective cancer therapies but their use is complicated by nephrotoxicity. Cancer immunotherapies exploit various properties of immune cells to enhance immune-mediated tumor killing. Interferon and high-dose interleukin-2 are older immunotherapies first employed clinically in the 1980s and 1990s to treat a number of different cancers. While effective, these two therapies have well-known systemic toxicities, which include acute kidney disease. The emergence of the new cancer immunotherapies over the past decade brings more effective treatment options. The immune checkpoint inhibitors and chimeric antigen receptor T cells are exciting additions to the cancer treatment armamentarium. These agents effectively treat a several and a growing list of cancers that have otherwise failed other therapies. However, as with the conventional and targeted cancer agents, drug-induced acute and chronic kidney disease is an untoward effect of this group of drugs. We will undertake a case-based review: the newer immunotherapies followed by the older therapies, interferon and interleukin-2.

show abstract

Interferon Induced Focal Segmental Glomerulosclerosis

Cited by 8 publications

References 14 publications

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association

The adverse kidney effects of cancer immunotherapies

Contact Info

Product

Resources

About